
Thomas J Carmody

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9926294/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial. Psychological Medicine, 2022, 52, 2441-2449.	2.7	6
2	Psychometric and Clinical Evaluation of the Clinician (VQIDS-C5) and Self-Report (VQIDS-SR5) Versions of the Very Quick Inventory of Depressive Symptoms. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 289-302.	1.0	3
3	Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder. Journal of Personalized Medicine, 2022, 12, 412.	1.1	7
4	Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial. Journal of Psychiatric Research, 2022, 149, 243-251.	1.5	4
5	Moderators of treatment response to exercise in participants with stimulant use disorder: Exploratory results from the Stimulant Reduction using Dosed Exercise (STRIDE)CTN-0037 study. Mental Health and Physical Activity, 2021, 21, 100421.	0.9	0
6	Comparison of inflammatory markers as moderators of depression outcomes: A CO-MED study. Journal of Affective Disorders, 2021, 295, 1066-1071.	2.0	3
7	The effectiveness of enhanced evidence-based care for depressive disorders: a meta-analysis of randomized controlled trials. Translational Psychiatry, 2021, 11, 531.	2.4	6
8	Effect of Intrinsic Patterns of Functional Brain Connectivity in Moderating Antidepressant Treatment Response in Major Depression. American Journal of Psychiatry, 2020, 177, 143-154.	4.0	76
9	Discovery and replication of cerebral bloodÂflow differences in major depressive disorder. Molecular Psychiatry, 2020, 25, 1500-1510.	4.1	28
10	Inflammation and Response to Sertraline Treatment in Patients With CKD and Major Depression. American Journal of Kidney Diseases, 2020, 75, 457-460.	2.1	6
11	A Systematic Review and Meta-Analysis of Depression and Protein–Energy Wasting in Kidney Disease. Kidney International Reports, 2020, 5, 318-330.	0.4	20
12	Comprehensive phenotyping of depression disease trajectory and risk: Rationale and design of Texas Resilience Against Depression study (T-RAD). Journal of Psychiatric Research, 2020, 122, 22-32.	1.5	21
13	Depression and the Effect of Sertraline on Inflammatory Biomarkers in Patients with Nondialysis CKD. Kidney360, 2020, 1, 436-446.	0.9	4
14	Predicting future suicidal events in adolescents using the Concise Health Risk Tracking Self-Report (CHRT-SR). Journal of Psychiatric Research, 2020, 126, 19-25.	1.5	14
15	Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse. Biological Psychiatry, 2020, 88, 657-667.	0.7	23
16	Positive and negative valence systems in major depression have distinct clinical features, response to antidepressants, and relationships with immunomarkers. Depression and Anxiety, 2020, 37, 771-783.	2.0	22
17	The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients. Journal of Psychopharmacology, 2019, 33, 185-193.	2.0	14
18	Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial. EClinicalMedicine, 2019, 10, 32-41.	3.2	19

THOMAS J CARMODY

#	Article	IF	CITATIONS
19	Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes. American Journal of Nephrology, 2019, 50, 37-47.	1.4	31
20	Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study. Journal of Psychiatric Research, 2019, 113, 165-171.	1.5	33
21	Pretreatment Rostral Anterior Cingulate Cortex Connectivity With Salience Network Predicts Depression Recovery: Findings From the EMBARC Randomized Clinical Trial. Biological Psychiatry, 2019, 85, 872-880.	0.7	48
22	Anxiety and anhedonia in depression: Associations with neuroticism and cognitive control. Journal of Affective Disorders, 2019, 245, 1070-1078.	2.0	17
23	The Concise Health Risk Tracking Selfâ€Report (CHRTâ€SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. Depression and Anxiety, 2019, 36, 313-320.	2.0	7
24	A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder. Journal of Psychiatric Research, 2018, 102, 65-71.	1.5	14
25	Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression. JAMA Psychiatry, 2018, 75, 547.	6.0	125
26	A complier average causal effect analysis of the Stimulant Reduction Intervention using dosed exercise study. Contemporary Clinical Trials Communications, 2018, 10, 1-8.	0.5	9
27	Test-retest reliability of cerebral blood flow in healthy individuals using arterial spin labeling: Findings from the EMBARC study. Magnetic Resonance Imaging, 2018, 45, 26-33.	1.0	28
28	Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial. Molecular Neuropsychiatry, 2018, 4, 7-19.	3.0	12
29	Adiponectin moderates antidepressant treatment outcome in the combining medications to enhance depression outcomes randomized clinical trial. Personalized Medicine in Psychiatry, 2018, 9-10, 1-7.	0.1	5
30	The Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors. BMC Cancer, 2018, 18, 744.	1.1	7
31	Psychometrics of the Self-Report Concise Associated Symptoms Tracking Scale (CAST-SR). Journal of Clinical Psychiatry, 2018, 79, 41-47.	1.1	5
32	Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of) Tj ETQq0 0 0 rgBT /O 6, 22-30.	verlock 10 0.5) Tf 50 227 1 22
33	Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence. JAMA - Journal of the American Medical Association, 2017, 318, 1876.	3.8	99
34	Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder. Journal of Clinical Psychiatry, 2017, 78, 1075-1082.	1.1	53
35	Affect Following First Exercise Session as a Predictor of Treatment Response in Depression. Journal of Clinical Psychiatry, 2016, 77, 1036-1042.	1.1	15
36	Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. Journal of Psychiatric Research, 2016, 78, 11-23.	1.5	216

THOMAS J CARMODY

#	Article	IF	CITATIONS
37	Atypical depressive symptoms as a predictor of treatment response to exercise in Major Depressive Disorder. Journal of Affective Disorders, 2016, 200, 156-158.	2.0	15
38	Performance of depression rating scales in patients with chronic kidney disease: an item response theory-based analysis. General Hospital Psychiatry, 2016, 42, 60-66.	1.2	9
39	Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial. American Journal of Psychiatry, 2016, 173, 1196-1204.	4.0	40
40	Brain imaging demonstrates a reduced neural impact of eating in obesity. Obesity, 2016, 24, 829-836.	1.5	17
41	Baseline medical comorbidities in adults randomized in the STRIDE trial for psychostimulant use disorders. American Journal on Addictions, 2016, 25, 215-220.	1.3	4
42	A COMPREHENSIVE EXAMINATION OF WHITE MATTER TRACTS AND CONNECTOMETRY IN MAJOR DEPRESSIVE DISORDER. Depression and Anxiety, 2016, 33, 56-65.	2.0	43
43	Decision-making processes as predictors of relapse and subsequent use in stimulant-dependent patients. American Journal of Drug and Alcohol Abuse, 2016, 42, 88-97.	1.1	23
44	Early Improvement in Psychosocial Function Predicts Longer-Term Symptomatic Remission in Depressed Patients. PLoS ONE, 2016, 11, e0167901.	1.1	26
45	Test–retest reliability of freesurfer measurements within and between sites: Effects of visual approval process. Human Brain Mapping, 2015, 36, 3472-3485.	1.9	136
46	A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline for Cocaine Dependence in Bipolar I Disorder. American Journal of Psychiatry, 2015, 172, 1014-1021.	4.0	30
47	Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study. American Journal of Psychiatry, 2015, 172, 881-891.	4.0	87
48	Exercise as an Augmentation Treatment for Nonremitted Major Depressive Disorder. Journal of Clinical Psychiatry, 2011, 72, 677-684.	1.1	177
49	The Montgomery Äsberg and the Hamilton ratings of depression: A comparison of measures. European Neuropsychopharmacology, 2006, 16, 601-611.	0.3	183
50	Making clinicians lives easier: Guidance on use of the QIDS self-report in place of the MADRS. Journal of Affective Disorders, 2006, 95, 115-118.	2.0	33
51	The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry, 2003, 54, 573-583.	0.7	2,981
52	Response in Relation to Baseline Anxiety Levels in Major Depressive Disorder Treated with Bupropion Sustained Release or Sertraline. Neuropsychopharmacology, 2001, 25, 131-138.	2.8	45
53	The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and Self-Report (IDS-SR) ratings of depressive symptoms. International Journal of Methods in Psychiatric Research, 2000, 9, 45-59.	1.1	328
54	Long-term results of interstitial implant in locally advanced cervical cancer:A retrospective study of 50 cases. Radiation Oncology Investigations, 1996, 4, 33-40.	1.3	2